Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sarepta Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
SRPT
Nasdaq
2836
www.sarepta.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sarepta Therapeutics, Inc.
Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts
- Feb 8th, 2025 2:18 pm
Nvidia And 2 Other High Growth Tech Stocks In The United States
- Feb 6th, 2025 2:01 pm
The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
- Feb 6th, 2025 10:23 am
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry
- Feb 5th, 2025 10:54 am
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
- Feb 3rd, 2025 12:43 pm
Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
- Jan 31st, 2025 1:36 pm
Sarepta could be down on patient death in FDA database, says RBC Capital
- Jan 30th, 2025 3:35 pm
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
- Jan 27th, 2025 6:00 am
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
- Jan 20th, 2025 12:52 pm
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
- Jan 13th, 2025 5:25 pm
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 6th, 2025 1:30 pm
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
- Jan 6th, 2025 12:40 pm
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec 31st, 2024 9:10 pm
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now?
- Dec 29th, 2024 11:45 am
Exploring High Growth Tech Stocks in the US December 2024
- Dec 26th, 2024 6:06 pm
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024?
- Dec 23rd, 2024 3:04 pm
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
- Dec 20th, 2024 10:21 am
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
- Dec 19th, 2024 6:24 pm
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
- Dec 19th, 2024 4:25 pm
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
- Dec 19th, 2024 1:45 pm
Scroll